在日常生活中,癌症的阴影始终笼罩着人们,而 结直肠癌 ...
On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...
Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.
The therapy, dubbed DNL343, is designed to activate the protein complex eIF2B, protecting neurons by preventing further aggregation of the TDP-43 protein. A phase 2/3 readout from a Massachusetts ...
The HEALEY platform trial is evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis (ALS). DNL343 is a novel small molecule ALS therapeutic candidate that targets eIF2B ...